ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Reengineered immune system cells show early promise against HIV … – Science Daily

Continue reading

2017-10-14 Michael Zand NEWS

First Gene Therapy For an Inherited Disease Could Soon Be Approved by The FDA – ScienceAlert

First Gene Therapy For an Inherited Disease Could Soon Be Approved by The FDAScienceAlertBy contrast, Luxturna, the Spark product, represents what is thought of as true gene therapy, in which a functional gene does the job of a defective one. About 1,… Continue reading

2017-10-14 Michael Zand NEWS

Dr. Choueiri on the Research With Immunotherapy in RCC – OncLive

Dr. Choueiri on the Research With Immunotherapy in RCCOncLiveToni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immu… Continue reading

2017-10-13 Michael Zand NEWS

Revamped CAR-T could curb HIV levels without antiretroviral drugs – FierceBiotech


Science Daily

Reengineered immune system cells show early promise against HIV …
Science Daily
Improving on a previous attempt, scientists have developed a new strategy that could potentially be used to reengineer a patient’s own immune system cells to …

and more »

Continue reading

2017-10-13 Michael Zand NEWS

Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million – MarketWatch


FierceBiotech

Revamped CAR–T could curb HIV levels without antiretroviral drugs
FierceBiotech
Adding a synthetic CAR protein to T cells makes them better able to fight a specific target, such as cancer or HIV. CAR-T therapy involves extracting a patient’s T cells, re-engineering them in a lab to express specific CAR proteins and then injecting …

and more »

Continue reading

2017-10-13 Michael Zand NEWS

Sastry stepping down as engineering dean – UC Berkeley

UC BerkeleySastry stepping down as engineering deanUC BerkeleyThis impressive assortment includes CITRIS and the Banatao Institute, Blum Center for Developing Economies, Berkeley Water Center, Synthetic Biology Institute, Qualcomm Swarm Lab, Center for… Continue reading

2017-10-13 Michael Zand NEWS

New markers could identify patients most at risk of brain damage from CAR T cell immunotherapy – Cancer Research UK

Cancer Research UKNew markers could identify patients most at risk of brain damage from CAR T cell immunotherapyCancer Research UKThe team, from the Fred Hutchinson Cancer Research Centre, identified a number of potential biomarkers that could help doc… Continue reading

2017-10-13 Michael Zand NEWS

Gene therapy for rare hereditary blindness marks “start of a new revolution” in medicine – CBS News

CBS NewsGene therapy for rare hereditary blindness marks "start of a new revolution" in medicineCBS NewsAn experimental gene therapy for a rare hereditary form of blindness is a step closer to reality. An FDA advisory panel voted unanimously … Continue reading

2017-10-13 Michael Zand NEWS
  • 1
  • …
  • 1,052
  • 1,053
  • 1,054
  • 1,055
  • 1,056
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

MarketWatch

Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million
MarketWatch
Spark Therapeutics’ gene therapy for an otherwise incurable rare eye disease, if approved, could be a major milestone for the disease itself as well as the field of gene therapy. The therapy, Luxturna, was recommended for approval by a Food and Drug …
Spark Therapeutics Inc. (ONCE) Moves Lower on Volume Spike for October 13Equities.com
Spark Therapeutics (NASDAQ:ONCE): BMO Capital Reconfirms “Outperform” Rating Today, Has a Target of $101/ShareWeeklyHub
19.91 % to Target, BMO Capital Reconfirms ‘Outperform’ Rating on Spark Therapeutics (NASDAQ:ONCE) Shares TodayFinance News Daily
Weekly Register
all 88 news articles »